Flucelvax

Flucelvax

Flucelvax Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

FLUCELVAX® is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine

FLUCELVAX is approved for use in persons 18 years of age and older.

History

There is currently no drug history available for this drug.

Other Information

FLUCELVAX (Influenza Vaccine), a vaccine for intramuscular injection, is a “subunit” influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells, a continuous cell line. These cells were adapted to grow freely in suspension in culture medium. The virus is inactivated with ß-propiolactone, disrupted by the detergent cetyltrimethylammonium bromide and purified through several process steps. Each of the 3 virus strains is produced and purified separately then pooled to formulate the trivalent vaccine.

FLUCELVAX is a sterile, slightly opalescent suspension in phosphate buffered saline. FLUCELVAX is standardized according to United States Public Health Service requirements for the 2015-2016 influenza season and is formulated to contain a total of 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following three influenza strains: A/Brisbane/10/2010 (wild type) (an A/California/7/2009 (H1N1)pdm09-like virus); A/South Australia/55/2014 (wild type) (an A/Switzerland/9715293/2013 (H3N2)-like virus); B/Utah/9/2014 (a B/Phuket/3073/2013-like virus).Each dose of FLUCELVAX may contain residual amounts of MDCK cell protein (≤8.4 mcg), protein other than HA (≤ 120 mcg), MDCK cell DNA (≤ 10 ng), polysorbate 80 (≤ 1125 mcg), cetyltrimethlyammonium bromide (≤ 13.5 mcg), and β-propiolactone (<0.5 mcg), which are used in the manufacturing process.

FLUCELVAX contains no preservative or antibiotics.

The tip caps of the pre-filled syringes may contain natural rubber latex.

Flucelvax Manufacturers


  • Novartis Vaccines And Diagnostics, Inc.
    Flucelvax (Influenza A Virus A/brisbane/10/2010 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/south Australia/55/2014 (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated) And Influenza B Virus B/utah/9/2014 Antigen (Mdck Cell Derived, Propiolactone Inactivated)) Injection, Suspension [Novartis Vaccines And Diagnostics, Inc.]
  • Novartis Vaccines And Diagnostics Gmbh
    Flucelvax (Influenza A Virus A/brisbane/10/2010 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/texas/50/2012 X-223a (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated), And Influenza B Virus B/massachusetts/2/2012 Antigen (Mdck Cell Derived, Propiolactone Inactivated)) Injection, Suspension [Novartis Vaccines And Diagnostics Gmbh]
  • Novartis Vaccines And Diagnostics, Inc.
    Flucelvax (Influenza A Virus A/brisbane/10/2010 (H1n1) Antigen (Mdck Cell Derived, Propiolactone Inactivated), Influenza A Virus A/texas/50/2012 X-223a (H3n2) Antigen (Mdck Cell Derived, Propiolactone Inactivated), And Influenza B Virus B/massachusetts/2/2012 Antigen (Mdck Cell Derived, Propiolactone Inactivated)) Injection, Suspension [Novartis Vaccines And Diagnostics, Inc.]

Login To Your Free Account